엠파글리플로진(자디앙) 시장 규모, 점유율 및 성장 분석 : 적응증별, 용량별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Empagliflozin (Jardiance) Market size was valued at USD 18.62 Billion in 2024 and is poised to grow from USD 20.74 Billion in 2025 to USD 49.2 Billion by 2033, growing at a CAGR of 11.4% during the forecast period (2026-2033).

Empagliflozin, known as Jardiance, stands at the forefront of the SGLT2-inhibitor market, which has experienced substantial growth due to the drug's efficacy in reducing cardiovascular mortality in individuals with type-2 diabetes. Its ability to enhance glucose control and minimize heart-failure risk has influenced prescribing trends, prompting insurers to prioritize it over traditional treatments. This shift has transitioned empagliflozin from a niche player to a billion-dollar entity integral to treatment guidelines across various regions. A notable trend is the broadening of its usage in heart failure and chronic kidney disease, bolstered by strong clinical evidence that enhances physician trust, formulary acceptance, and reimbursement. Consequently, sustained double-digit growth is anticipated as the drug extends its reach in emerging markets grappling with metabolic diseases.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Empagliflozin (Jardiance) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Empagliflozin (Jardiance) Market Segments Analysis

Global empagliflozin (jardiance) market is segmented by indication, dosage strength, distribution channel, end user and region. Based on indication, the market is segmented into type 2 diabetes, heart failure and chronic kidney disease. Based on dosage strength, the market is segmented into 10 mg and 25 mg. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on end user, the market is segmented into hospitals, clinics and home care. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Empagliflozin (Jardiance) Market

The growing prevalence of type 2 diabetes worldwide leads to an ongoing demand for effective glucose-lowering therapies, establishing empagliflozin as a favored choice due to its demonstrated cardiovascular advantages. Healthcare professionals increasingly emphasize treatments that not only manage blood sugar levels but also mitigate associated health risks, resulting in a wider adoption of this medication in both primary and specialty care settings. Additionally, heightened patient awareness regarding the long-term complications of diabetes encourages individuals to pursue treatments that promise better health outcomes. This increased endorsement facilitates the inclusion of empagliflozin in formulary lists globally, further boosting its market presence.

Restraints in the Global Empagliflozin (Jardiance) Market

The Empagliflozin (Jardiance) market faces significant challenges due to its relatively high pricing when compared to generic antidiabetic medications, which raises affordability concerns for budget-conscious healthcare systems. In many areas with constrained healthcare funding, payers tend to favor more economical alternatives, thereby hindering Empagliflozin's market penetration. Additionally, high out-of-pocket costs for patients can negatively impact treatment adherence, particularly in situations where insurance does not offer comprehensive coverage. This financial burden limits broader adoption of the drug and stifles market growth, despite its clinical benefits. Additionally, discussions around pricing reductions may experience delays, further impacting the drug's availability in various regions.

Market Trends of the Global Empagliflozin (Jardiance) Market

The global empagliflozin (Jardiance) market is experiencing a notable trend toward expanding its therapeutic indications beyond traditional diabetes treatment. Pharmaceutical companies are increasingly focusing on clinical trials that highlight empagliflozin's efficacy in managing cardiovascular, renal, and heart failure conditions. This multi-indication approach not only attracts specialty physicians but also enhances formulary placements and integrates empagliflozin into comprehensive chronic disease management programs. As insurers begin to recognize the economic and therapeutic value of a single medication that addresses multiple comorbidities, there is a shift in prescribing patterns toward earlier adoption, thus driving market growth and creating new opportunities across key healthcare markets globally.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Empagliflozin (Jardiance) Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Type 2 Diabetes
• Heart Failure
• Chronic Kidney Disease

Global Empagliflozin (Jardiance) Market Size by Dosage Strength & CAGR (2026-2033)

• Market Overview
• 10 mg
• 25 mg

Global Empagliflozin (Jardiance) Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Empagliflozin (Jardiance) Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Home Care

Global Empagliflozin (Jardiance) Market Size & CAGR (2026-2033)

• North America (Indication, Dosage Strength, Distribution Channel, End User)
  • US
  • Canada
• Europe (Indication, Dosage Strength, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Indication, Dosage Strength, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Indication, Dosage Strength, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Indication, Dosage Strength, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkem Laboratories Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Macleods Pharmaceuticals Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MSN Laboratories Pvt. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hetero Labs Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz Group AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• STADA Arzneimittel AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations